





Talzenna® (talazoparib) Prior Authorization Form

Prescriber Phone:	Member Name:	Date of Birth:_	Member ID#:	
Pharmacy NPI: Pharmacy Name: Pharmacy Phone: Pharmacy Phone: Pharmacy Phone: Pharmacy Phone: Pharmacy Phone: Prescriber Information Prescriber NPI: Prescriber Name: Prescriber Name: Specialty: Criteria For Initial Authorization: 1. Please indicate diagnosis and information: Prescriber Phone: Pres	Drug Information			
Pharmacy NPI:	Pharmacy billing (NDC:)	Start Date (or date of next dose):	
Pharmacy NPI:	Dose:		Regimen:	
Prescriber Information Prescriber NPI:	Pharmacy Information			
Prescriber NPI:	Pharmacy NPI: Pharmacy Name:			
Prescriber NPI:	Pharmacy Phone:	Phari	macy Fax:	
Prescriber Phone:	Prescriber Information			
Criteria For Initial Authorization: 1. Please indicate diagnosis and information: Breast Cancer A. Metastatic or recurrent breast cancer? Yes No	Prescriber NPI: Prescriber Name:			
For Initial Authorization: 1. Please indicate diagnosis and information: Breast Cancer A. Metastatic or recurrent breast cancer? Yes No B. Human epidermal growth factor receptor 2 (HER2)-status? Positive Negative C. Positive test for BRCA 1/2-germline mutation? Yes No D. Hormone receptor (HR)-positive? Yes No i. If yes, has member failed prior endocrine therapy or considered to not be a candidate for endocrine therapy? Yes No E. Hormone receptor (HR)-negative? Yes No F. Does member have symptomatic visceral disease? Yes No G. Will talazoparib be used as a single agent? Yes No Prostate Cancer A. Is disease metastatic, castration-resistant prostate cancer? Yes No B. Is disease homologous recombination repair (HRR) gene-mutated? Yes No C. Will talazoparib be used in combination with enzalutamide? Yes No If diagnosis is not listed above, please indicate diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on talazoparib? Yes No If yes, please specify adverse reactions:	Prescriber Phone:	Prescriber Fax:_	Specialty:	
1. Please indicate diagnosis and information: Breast Cancer	Criteria			
rieschoer alonature: Date:	A. Metastatic or recurrent breast cancer? Yes No B. Human epidermal growth factor receptor 2 (HER2)-status? Positive Negative C. Positive test for BRCA 1/2-germline mutation? Yes No D. Hormone receptor (HR)-positive? Yes No i. If yes, has member failed prior endocrine therapy or considered to not be a candidate for endocrine therapy? Yes No E. Hormone receptor (HR)-negative? Yes No F. Does member have symptomatic visceral disease? Yes No G. Will talazoparib be used as a single agent? Yes No Prostate Cancer A. Is disease metastatic, castration-resistant prostate cancer? Yes No B. Is disease homologous recombination repair (HRR) gene-mutated? Yes No C. Will talazoparib be used in combination with enzalutamide? Yes No If diagnosis is not listed above, please indicate diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on talazoparib? Yes No If yes, please specify adverse reactions:			
Prescriber Signature: Date: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the	Prescriber Signature:	tmont is modically roce	Date:	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

best of my knowledge.

AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 112 10/25/2023